… , HER2-positive early breast cancer, according to findings … + early breast cancer: trastuzumab (Herceptin) alone, lapatinib (Tykerb) alone, … 47;HER2-positive early breast cancer: An exploratory analysis … at: 2025 San Antonio Breast Cancer Symposium; December 9– …

… 2-positive (HER2+) metastatic breast cancer (mBC). The trial, HER2CLIMB … ) including pyrotinib (Irene), lapatinib (Tykerb), tucatinib, neratinib (Nerlynx), and afatinib … and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05). ClinicalTrials.gov. …

… receptor 2 (HER2) positive breast cancer. These medications are typically administered … . Other drugs, like lapatinib (Tykerb) and tucatinib (Tukysa), both … treatment of advanced HER2-positive breast cancer. Capecitabine (Xeloda) and cyclophosphamide …

… Predictive Genomics in Breast Cancers Predictive genomics in breast cancer falls into 2 … lapatinib (Tykerb). Determination of the HER2 status of breast cancer is the … J. Breast cancer cell line classification and its relevance with breast tumor subtyping. …

… , whose groundbreaking innovations in breast cancer treatment have benefited millions … develop groundbreaking treatments for other breast cancer subtypes, including palbociclib, approved … therapies like Tukysa, Nerlynx, Tykerb and Avastin by other …

… (HER2)-mutated metastatic breast cancer (mBC). The data … for Medical Oncology Breast Cancer 2025 Annual Meeting … Genentech, Roche), lapatinib (24%; Tykerb; Novartis), trastuzumab deruxtecan (9% … HER2-mutated metastatic breast cancer, particularly those who …

… resistant advanced HER2-postive breast cancer,” lead study author … , incurable HER2-positive breast cancer, irrespective of PD- … 4%; 17%) and lapatinib (Tykerb; 20%; 12%; 6%). Most … breast cancer: BCT1703 DIAmOND. Presented at: 2025 ESMO Breast Cancer Congress …

… patients with HER2-positive metastatic breast cancer who had previously received HER2 … advanced or metastatic HER2-expressing breast cancer with an ECOG performance status … ; 73%), pertuzumab (87%; 67%), lapatinib (Tykerb; 23%; 27%), tucatinib (6%; 13% …

… with HER2-positive metastatic breast cancer and again when it … survival (PFS) vs lapatinib (Tykerb) plus capecitabine and showed … Congress on the Future of Breast Cancer® (IBC) occurring on … ;West...[for] HER2-positive breast cancer in the curative setting, …

… known for his innovations in breast cancer treatment. According to Dr. … therapy for HER2-positive breast cancer approved by the U … ) for advanced ER-positive breast cancer subtypes and ribociclib (approved … such as Tukysa, Nerlynx, Tykerb, and Avastin by other …